NBIX
Neurocrine Biosciences
$176.41
+$0.63 (+0.36%)Jul 27, 2026
Key metrics
The numbers that frame NBIX today
- Market cap
- $17.74B
- P/E (TTM)
- 26.5
- EV / FCF
- 21.5
- Gross margin
- 98.2%
- EV / Sales
- 5.8
- ROIC
- 25.1%
- Div yield
- 0%
- Debt / equity
- 0.1
- 52wk Low
- $122.14
- 52wk High
- $181.18
Growth
Revenue and earnings trend for NBIX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about NBIX
Is Neurocrine Biosciences a good buy?
Yes. Neurocrine Biosciences has excellent quality and excellent momentum. Both signals support the setup. Growth looks excellent, which supports the long-term business case. We think Neurocrine Biosciences is selling at a low price.
What is the market capitalization of NBIX?
Neurocrine Biosciences's market capitalization is $17.74B.
What is the P/E ratio for NBIX stock?
Neurocrine Biosciences's current P/E ratio is 26.5.
What is the 52-week high for NBIX stock?
The 52-week high for Neurocrine Biosciences is $181.18. The current close of $176.41 is 2.6% below that high.
What is the 52-week low for NBIX stock?
The 52-week low for Neurocrine Biosciences is $122.14. The current close of $176.41 is 44.4% above that low.
Does NBIX stock pay dividends?
Neurocrine Biosciences does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for NBIX?
Neurocrine Biosciences's Debt / Equity ratio is 0.12.